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OBJECTIVES We sought to study the expression of bradykinin type-2 receptors (BK-2Rs) in patients with
heart failure (HF).
BACKGROUND Recent work in experimental animals has suggested that bradykinin (BK) exerts cardiopro-
tective effects through specific BK-2Rs. However, nothing is known about the regulation of
BK-2R expression in the pathogenesis of human HF.
METHODS Human heart tissue was obtained from excised hearts of patients undergoing cardiac
transplantation (n  13) and from normal hearts (n  6) unsuitable for donation. The
patients had HF due to idiopathic dilated cardiomyopathy (IDC) (n  7) or coronary heart
disease (CHD) (n  6). Tissue samples from the left ventricles were analyzed by competitive
reverse-transcriptase-polymerase chain reaction and Western blotting for the expression of
BK-2R messenger ribonucleic acid (mRNA) and protein.
RESULTS In both the IDC and CHD hearts, the level of BK-2R mRNA expression was found to be
significantly lower (30% and 38% of control values, respectively) than that in normal hearts.
Correspondingly, the BK-2R protein level was significantly reduced in both the IDC and
CHD hearts (45% and 62% of control values, respectively) and apparently involved all
myocardial cell types. The down-regulation of BK-2R expression in failing hearts did not
correlate with decreased cellularity or with the expression pattern of other members of the
G-protein–coupled receptor superfamily. However, BK-2R down-regulation in the failing
hearts was associated with a decrease in endothelial nitric oxide synthase in both IDC (53%
of control value) and CHD (43% of control value) hearts.
CONCLUSIONS These results are the first to suggest that a loss of BK-2Rs is involved in the pathogenesis of
human HF. (J Am Coll Cardiol 2002;40:119–25) © 2002 by the American College of
Cardiology Foundation
Recent work in experimental animals has suggested that
kinins, notably bradykinin (BK) and kallidin, have both
short- and long-term cardioprotective effects. The short-
term effects include protection of the myocardium from
ischemia-reperfusion injuries (1–4), whereas the long-term
effects involve both a reduction in left ventricular hypertro-
phy (LVH) and prevention of heart failure (HF) (5–7).
The cardioprotective effects of kinins seem to be medi-
ated by stimulation of bradykinin type-2 receptors (BK-
2Rs) and involve the production and release of vasodilating
nitric oxide by endothelial cells (3,8), together with both
antiproliferative (9) and antihypertrophic (10) effects on
fibroblasts and myocytes. Whether these cardioprotective
effects are mediated by improved hemodynamics or direct
effects on target cells, or both, is presently unknown.
In contrast to experimental animal models, the cardio-
protective role of the kinin system, especially the role of BK
receptors in the prevention of human HF, is unknown.
Herein, we show that the expression levels of the cardio-
protective BK-2Rs in failing human hearts are significantly
reduced and that the receptor down-regulation is associated
with a decrease in endothelial nitric oxide synthase (eNOS).
Our novel results suggest the involvement of BK-2Rs in the
pathogenesis of human HF.
METHODS
Preparation of human heart samples. Normal heart sam-
ples (n  6) were obtained from the left ventricles of organ
donors who had no history of cardiac disease and who had
been excluded from organ donation because of age, body
size or blood type incompatibilities. Failing left ventricles
were harvested at the time of cardiac transplantation from
13 patients with end-stage HF due to either idiopathic
dilated cardiomyopathy (IDC) (n  7) or coronary heart
disease (CHD) (n  6) at the University Central Hospital,
Helsinki, Finland, or at the General Hospital, Vienna,
Austria. All patients were treated with a combination of
drugs, including beta-blockers, angiotensin-converting en-
zyme (ACE) inhibitors, loop diuretics, digoxin and spirono-
lactone. In addition, a 53-year-old man with CHD who was
not treated with an ACE inhibitor was included in the
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analysis as a control for the effect of ACE inhibitors on
BK-2R expression. After excision, the heart tissues were
immediately frozen in liquid nitrogen and stored at 70°C.
Myocardium devoid of visible scar tissue was used in the
experiments. The clinical characteristics of the patients in
this study are shown in Table 1. The Internal Review
Committees at the corresponding hospitals approved the
use of the human heart samples.
Competitive reverse transcriptase-polymerase chain re-
action (RT-PCR). Total ribonucleic acid (RNA) was iso-
lated from human heart samples using an ultra-pure TRIzol
reagent (Gibco BRL) and a RNeasy Mini Kit (Qiagen).
One microgram of purified total RNA was transcribed into
complementary DNA using a Superscript pre-amplification
system (Gibco BRL). The primers were as follows—BK-
2R: 5-CACCATCTCCAACAACTTCG (sense), 5-
GGTAGCTGATGACACAAGCG (anti-sense);
glyceraldehyde-3-phosphate dehydrogenase (GAPDH): 5-
ACCACAGTCCATGCCATCAC (sense) , 5 -
TCCACCACCCTGTTGCTGTA (anti-sense); angio-
tensin II type 1 receptor (AT-1R): 5-GCTTCTTGG-
TGGATGAGCTT (sense), 5-GCTGGCCCTTT-
GGCAAT TAC (anti-sense); and angiotensin II type 2
receptor (AT-2R): 5-TTCCCTTCCATGTTCTG-
ACC (sense), 5-AAACACACTGCGGA GCTTCT
(anti-sense). The competitor DNA for BK-2R was obtained
by inserting a 129-base pair external DNA fragment into
the SacI site. The polymerase chain reaction (PCR) product
was verified by DNA sequencing to represent the corre-
sponding target. The use of equal amounts of messenger
RNA in the RT-PCR assays was confirmed by analyzing
the expression levels of GAPDH (data not shown). The
PCR products were quantitated with a Gel Doc 2000
gel-documentation system (Bio-Rad), and the logarithm of
the target-to-competitor ratio was plotted against the log-
arithm of the competitor DNA molecules (11).
Detection of BK-2Rs and eNOS by Western blotting.
Triton-X-100 extracts were prepared from normal and
failing heart tissues subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blotting (12). The BK-2Rs were detected using a
monoclonal BK-2R antibody (0.25 mg/l, Transduction
Laboratories), a peroxidase-conjugated goat anti-mouse an-
tibody (0.001 mg/l, Dako) and enhanced chemilumines-
cence (Amersham Pharmacia Biotech), according to the
manufacturers’ recommendations. The eNOS was detected
using a polyclonal anti-human eNOS antibody (0.2 mg/l,
R&D Systems) and a peroxidase-conjugated rabbit anti-
goat antibody (0.001 mg/l, Dako). The blots were quanti-
tated with a Gel Doc 2000 gel-documentation system
(Bio-Rad), and the levels of BK-2R and eNOS expression
in failing hearts were expressed as the mean percentage 
SEM of control values (normal heart samples).
Expression of BK-2Rs in human coronary artery endo-
thelial cells. Human coronary artery endothelial cells
(HCAECs) (Clonetics) were cultured in endothelial cell
basal medium-2 media (Clonetics) supplemented with 5%
fetal bovine serum and growth factors (Bulletkit, Clonetics,
CC-3202) at 37°C under 5% carbon dioxide, as recom-
mended by the manufacturer. Subconfluent HCAECs were
incubated with an ACE inhibitor (10 M, captopril) in the
absence or presence of excess BK (10 nM) for 18 h in
serum-free culture media. Total RNA was isolated using an
RNeasy Mini Kit (Qiagen), and the expression of BK-2Rs
was determined using RT-PCR, as described previously.
Staining of normal and failing hearts. Serial frozen sec-
tions of normal and failing human hearts were stained for
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
AT-1R  angiotensin II type 1 receptor
AT-2R  angiotensin II type 2 receptor
BK  bradykinin
BK-2R  bradykinin type-2 receptor
CHD  coronary heart disease
DNA  deoxyribonucleic acid
eNOS  endothelial nitric oxide synthase
GAPDH  glyceraldehyde-3-phosphate dehydrogenase
HCAEC  human coronary artery endothelial cell
HF  heart failure
IDC  idiopathic dilated cardiomyopathy
LVH  left ventricular hypertrophy
PCR  polymerase chain reaction
RNA  ribonucleic acid
RT-PCR  reverse-transcriptase polymerase chain
reaction
Table 1. Characteristics of Patients
Patient
No. Etiology Gender
Age
(yrs)
ACE
Inhibitor
Therapy
1 Normal M 19 No
2 M 43 No
3 M 49 No
4 M 24 No
5 M 31 No
6 F 50 No
36  5*
7 CHD M 61 Yes
8 M 60 Yes
9 M 55 Yes
10 M 52 Yes
11 M 60 Yes
12 M 53 Yes
57  2*
13 IDC M 29 Yes
14 M 60 Yes
15 M 46 Yes
16 M 56 Yes
17 M 55 Yes
18 M 56 Yes
19 M 63 Yes
52  4*
*Average  SEM.
ACE  angiotensin-converting enzyme; CHD  coronary heart disease; IDC 
idiopathic dilated cardiomyopathy.
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fibrosis by using a commercial Masson trichrome staining
kit (Accustain, Sigma Diagnostics) and for BK-2Rs by
using a monoclonal anti–BK-2R antibody (5 mg/l, Trans-
duction Laboratories). Equal amounts of nonimmune serum
or phosphate-buffered saline were used to control the
specificity of antibodies. Control sections were stained for
smooth muscle cells (monoclonal anti–alpha-smooth mus-
cle cell actin antibody (3 mg/l; Sigma), endothelial cells
(rabbit polyclonal anti–von Willebrand factor antibody
(26 mg/l; Dako) and fibroblasts (monoclonal anti-human
prolyl-4-hydroxylase antibody (3 mg/l; Dako). The density
of the Masson trichrome (blue color  fibrosis; red color 
myocytes) and the antibody-peroxidase–generated color
(reddish-brown) in the stained frozen sections were quan-
titated using the Image-Pro Plus (version 4.0/4.1) image
analysis system (Media Cybernetics).
Statistical analysis. Data are expressed as the mean value 
SEM. All three patient groups showed normal distribution
when analyzed with the Shapiro-Wilks W test, and com-
parisons between the groups of normal and failing hearts
were made using two-way analysis of variance with Dun-
nett’s post-hoc test. Statistical significance was accepted at
p  0.05.
RESULTS
Expression of BK-2Rs mRNA in normal and failing
hearts. Figure 1A shows a representative competitive RT-
PCR analysis of BK-2Rs in three individual samples ran-
domly chosen from each subject group. The mRNA levels
of the cardioprotective BK-2Rs (Fig. 1B) were found to be
significantly decreased in hearts with either IDC (30% of
control value, p  0.003; middle row) or CHD (38% of
control value, p  0.01; right row), as compared with
normal hearts (left row). The competitive RT-PCR assay
was standardized to the expression level of GAPDH.
Furthermore, the observed down-regulation was specific for
BK-2Rs, because the expression of other members of the
G-protein– coupled receptor superfamily in the failing
hearts (Fig. 1C) was either induced (AT-1Rs) or unaffected
(AT-2Rs). In addition, incubating cultured HCAECs,
which express BK-2Rs in a constitutive manner, with an
ACE inhibitor (10 M, captopril) in the presence or
absence of excess BK (10 nM) for 18 h did not affect their
levels of BK-2R expression (Fig. 1D).
Bradykinin-2R protein in normal and failing hearts. As
shown in Figure 2, the protein levels of BK-2Rs were
significantly reduced both in IDC (45% of control value,
p  0.002; Fig. 2, middle bar) and CHD (62% of control
value, p  0.04; Fig. 2, right bar) hearts, as compared with
normal hearts (Fig. 2, left bar). In keeping with the
aforementioned results (Figs. 1 and 2), positive staining for
BK-2Rs, quantitated as the extent of reddish-brown inten-
sity, was clearly less in both IDC (42% of control value) and
CHD (65% of control value) hearts, as compared with
normal hearts (100%) (Figs. 3A to 3C). By staining serial
tissue sections with Masson trichrome and quantitating the
level of fibrosis (blue color), we found that the observed
reduction in BK-2R expression was associated with a
significantly higher degree of fibrosis (20.6  1.7% vs.
16.0  2.9% in normal samples; p  0.05) in IDC hearts
Figure 1. Quantitative reverse transcription-polymerase chain reaction of bradykinin type-2 receptors (BK-2Rs) in human hearts. (A) Messenger
ribonucleic acid (mRNA) expression of BK-2Rs in normal and failing human hearts. (B) The mRNA levels of BK-2Rs are shown as the log ratios between
the target and its competitor in the three patient groups. The solid triangle indicates a patient with coronary heart disease (CHD) who did not receive
an angiotensin-converting enzyme inhibitor. (C) Expression levels of angiotensin II type I and II receptors (AT-1R and AT-2R, respectively) were analyzed
in normal and failing hearts. (D) Levels of BK-2Rs were determined in bradykinin (BK)- and/or captopril (Capto)-treated cultured human coronary artery
endothelial cells (HCAEC). *p  0.01. **p  0.003. IDC  idiopathic dilated cardiomyopathy; M  marker.
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(Fig. 3E). However, the degree of fibrosis (20.3  8.3%) in
the CHD samples (Fig. 3F) was not significantly different
from that in the normal myocardium (16.0  2.9%).
Immunohistochemical staining of BK-2Rs. To localize
the BK-2Rs within the myocardial cell population, we
immunostained left ventricular tissue sections by using
specific antibodies for BK-2Rs and specific markers of the
individual myocardial cell types. Figure 4A shows sections
of normal myocardium with intramyocardial branches of
coronary arteries. All of the major cell types were found to
express BK-2Rs: endothelial cells (Fig. 4, upper left panel,
long white arrow), smooth muscle cells (Fig. 4, upper left
and middle panels, short white arrow) and fibroblasts, both
in the fibrotic area surrounding the vessels (Fig. 4, upper left
panel, short black arrow) and in the myocardial interstitium
(upper right panel, short black arrow). Also, the myocytes
were found to express BK-2Rs (Fig. 4, upper left panel, long
black arrow and inset showing the selected myocyte at a
higher magnification). The myocardial localization of en-
dothelial cells (Fig. 4A, lower left panel), smooth muscle
cells (lower middle panel) and interstitial fibroblasts (lower
right panel) was further verified by cell-specific staining of
serial sections of normal hearts. Interestingly, by grossly
comparing the BK-2R–positive cells in normal and failing
hearts, we found no apparent differences in their cell-
specific BK-2R expression pattern (Fig. 4B).
Expression of eNOS in normal and failing hearts.
Because the physiologic effects of BK, including vasodila-
tion, inhibition of myocardial growth and anti-ischemic
effects, are largely mediated through BK-2R–stimulated
expression and activation of eNOS (13–15), we measured
the expression level of eNOS in normal and failing hearts.
As shown in Figure 5, the observed decrease in BK-2R
expression in failing hearts was associated with a decrease in
eNOS expression in both IDC (53  5% of control value,
p  0.001) and CHD (44  10% of control value, p 
0.002) hearts.
DISCUSSION
The present results, showing a differential expression of
BK-2Rs in normal and failing hearts, are the first to suggest,
to the best of our knowledge, that BK-2Rs may be involved
in the pathogenesis of human HF. It has recently been
shown that BK-2R knockout mice develop LVH and HF
(16), suggesting that the BK-2R signaling system is essen-
tial for the regulation of myocardial growth and prevention
of HF. These data raise the possibility that the regulation of
myocardial growth and prevention of human HF may
depend on the presence of an intact BK-2R signaling
system. Thus, down-regulation of BK-2R expression in
failing human hearts, as shown in this study, may reflect a
maladaptive response in the pathogenesis of HF. Recently,
a direct regulatory link between BK-2Rs and eNOS was
shown in both normotensive (14) and ischemic (15) rats,
suggesting that the level of eNOS and the amount of nitric
oxide may partly depend on the level of BK-2Rs. Similarly,
in our present study, the down-regulation of BK-2Rs in
failing human hearts was associated with a significant decrease
in eNOS, a finding compatible with the idea that the reduced
amount of BK-2Rs may affect the level of eNOS.
BK-2Rs as a part of the cardioprotective system. During
the early stages of a pathologic process in the myocardium
that may ultimately lead to HF, LVH develops as a
compensatory “remodeling” mechanism, whereas the later
stages of the process are characterized by a loss of myocytes,
with subsequent left ventricular dysfunction and HF. Thus,
if BK-2Rs are an essential part of the cardioprotective
system, as has been suggested (4,16), a logical adaptive
response to the onset of such a pathologic process would be
Figure 2. Western blotting of bradykinin type-2 receptors (BK-2Rs) in human hearts. (A) Representative Western blot showing the expression of BK-2R
proteins in normal and failing human hearts. Equal amounts of protein (30 g/lane) were loaded onto the gel. (B) The relative amounts of BK-2Rs were
quantitated in the different patient groups by measuring the optical densities (OD) in the Western blots. *p  0.04. **p  0.002. CHD  coronary heart
disease; IDC  idiopathic dilated cardiomyopathy.
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an increase in BK-2R expression. Therefore, it is possible
that BK-2R expression is induced during the early stages of
the disease (i.e., LVH) and that the observed receptor
down-regulation occurs only later, at the stage of HF. To
settle this important question, serial samples of myocardial
tissue should be analyzed at different time points during the
pathogenesis of HF. Unfortunately, such an experimental
set-up in human HF is not feasible at present.
BK-2R polymorphism. Recently, an altered frequency of a
promoter (58T/C) polymorphism of the BK-2R gene has
been described in hypertensive African-American (17) and
Japanese (18) subjects, suggesting that decreased transcrip-
tional activity of the BK-2R promoter may be involved in
essential hypertension. Indeed, a partial genetic deficiency
(heterozygotes) of BK-2Rs in mice is already sufficient for
the onset of LVH (16). Thus, we cannot exclude the
possibility that patients with the phenotype of end-stage
HF have a genetically determined malfunction in their
BK-2R expression system, which could affect the balance
between cardiac risk factors and the cardioprotective system.
Further elucidation of the potential role of a hereditary
dysfunction of the BK-2R gene in the pathogenesis of HF
requires studies on the linkage between a HF phenotype and
possible BK-2R polymorphism.
BK-2R expression and ACE inhibitors. Because ACE
inhibitors are generally thought to exert their cardioprotec-
Figure 3. Detection of bradykinin type-2 receptors (BK-2Rs) and fibrosis in human hearts. Serial sections of normal (A and D), idiopathic dilated
cardiomyopathy (IDC) (B and E) and coronary heart disease (CHD) (C and F) hearts were analyzed for BK-2R expression (A to C) by using a monoclonal
BK-2R antibody (magnification 200) and for the degree of fibrosis (D to F) by Masson trichrome staining (magnification 200).
Figure 4. Detection of bradykinin type-2 receptors (BK-2Rs) and myocardial cells in human hearts. (A) Serial frozen sections of normal hearts were
analyzed for cell-specific BK-2R expression (magnification 400) and for specific antibodies in endothelial cells (EC), smooth muscle cells (SMC) and
fibroblasts (Fb). A BK-2R–positive myocyte (upper left panel, long black arrow and inset showing the selected myocyte at a higher magnification
[1,000]), an EC (long white arrow), a SMC (short white arrow) and a Fb (short black arrow) are also indicated in the upper left panel. (B) Frozen
sections of normal, idiopathic dilated cardiomyopathy (IDC) and coronary heart disease (CHD) hearts were stained for BK-2R expression (magnification
200).
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tive effects by inhibiting the production of angiotensin II
and by increasing the concentration of BK, it is relevant to
ask the question whether ACE inhibition also may affect the
level of BK-2R expression. Recent observations show that
BK levels in the human plasma of HF patients treated with
ACE inhibitors are similar to BK levels in healthy persons
(19), suggesting that the down-regulation of BK-2Rs ob-
served in the present study occurs independent of BK levels.
Furthermore, the fact that the beneficial effects obtained by
ACE inhibitors are inhibited by HOE-140, a specific
BK-2R antagonist, does not support a suppressive role of
ACE inhibitors in BK-2R expression. In the present study,
we had an opportunity to analyze a heart sample from an
additional patient with CHD who had not received an ACE
inhibitor (Fig. 1B, black triangle), and the BK-2R expres-
sion was not different from that of patients with CHD
treated with ACE inhibitors. In addition, incubating
HCAECs, which express BK-2Rs in a constitutive manner,
with an ACE inhibitor in the presence or absence of excess
BK for 18 h did not affect their levels of BK-2R expression.
However, although it appears unlikely that the observed
down-regulation of BK-2R expression in the failing hearts
is due to the presence of ACE inhibitors, we cannot
completely exclude the possibility that long-term adminis-
tration of ACE inhibitors may have an effect on the level of
receptor expression.
Cell-specific expression of BK-2Rs. The observed down-
regulation of BK-2Rs seems not to be cell-specific, because
not only the cells in the intramyocardial vascular tree (i.e.,
endothelial cells and smooth muscle cells) but also the cells
in the myocardial interstitium (i.e., fibroblasts and contrac-
tile cells [cardiomyocytes]) are affected. Whether the recep-
tor down-regulation is organ-specific is not known. This
question is not possible to answer because, due to ethical
reasons, samples of other organs from patients with end-
stage HF cannot be obtained. Because the functional role
and importance of BK-2Rs are likely to vary among the
different cell types, further experiments are necessary to
answer the challenging questions regarding the cell-specific
role of BK-2Rs in the pathogenesis of human HF.
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